NCT03560804|Completed
Loading search results
Sponsor study identifier
interventional
60
1 country
1
Study Start
November 10, 2014
Actual (reported)Primary Completion
September 15, 2017
Actual (reported)Study Completion
September 15, 2017
Actual (reported)The principal aim of the study is to determine whether the hemodynamic parameters measured with the two methods -impedance cardiography and applanation tonometry- can be predictive of the antihypertensive effect of two different classes of drugs, ATII antagonists and diuretics. The drugs that will be used in the study are olmesartan and chlorthalidone and the duration of the study is 12 months. The other basic aim of the study is to determine whether there is a difference (\>6mmHg) between the two drugs regarding the reduction of the mean 24hour blood pressure and the effect of them on the hemodynamic parameters. The hemodynamic parameters that will be measured by applanation tonometry are augmentation index, central blood pressure and pulse wave velocity. The hemodynamic parameters that will be measured by impedance cardiography are cardiac index, thoracic fluid content index, systemic vascular resistance index and others.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 15, 2017
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 10, 2014
Actual (reported)January 15, 2015
Actual (reported)September 15, 2017
Actual (reported)September 15, 2017
Actual (reported)June 18, 2018
Actual (reported)Pulse wave velocity
Measured by Sphygmocor devive
12 weeks
Systemic vascular resistance
12 months
Ambulatory blood pressure
12 months
ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target
Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target
Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
Hypertension Excellence Center, AHEPA University Hospital
Thessaloniki, 54635, Greece
Zebekakis Pantelis, Professor
Hypertension Excellence Center, 1st Department of Internal Medicine, AHEPA University Hospital
60 participants (actual enrollment reported by the registry).
First Submitted
January 15, 2015
First Posted
June 18, 2018
Study Start
November 10, 2014
Actual (reported)Postprandial Effects of Bean and Whole Grain Consumption on Arterial Stiffness
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
September 15, 2017
Actual (reported)Study Completion
September 15, 2017
Actual (reported)Last Updated
June 18, 2018
Record last verified: 2018-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: